Quantum BioPharma Ltd. reported Q2 2026 financial results and announced FDA approval for its Lucid-MS Phase 2 clinical trial in progressive multiple sclerosis. Cash, cash equivalents, and digital assets totaled US$9.5 million as of June 30, 2026, up from US$4.1 million at year-end 2025, providing a runway to October 2027 based on current burn rates. Operating expenses decreased 53% year-over-year to US$2.29 million, while total shareholders' equity rose 19% to US$6.09 million. The company operates in the biopharmaceutical industry, developing treatments for neurodegenerative and metabolic disorders.